Summer Sale
50% off Premium Yearly
00days
00hrs
00mins
00secs
Opinions Norman Levine
Teva PharmaceuticalTEVATOP PICKDec 28, 2016
Norman LevineOwned
$35.93
Stock price when the opinion was issued
$31.48
As of Jun 18, 2026. Market Open.
biotechnologypharmaceutical
It's the ideal tool to help you make quicker, more informed decisions for managing and tracking your investments.
You might be interested:
HOLD
Generic brand companies like Teva have struggled in the last 5 years has they competed with each others. Pfizer is in the process of buying one of their competitors and the Pfizer stock dropped 5$ on the announcement. Doesn't own Teva, purchased United Heatlth recently. You can hold but it's not a name he would hold due to the risk and they have no value added.
biotechnologypharmaceutical
DON'T BUY
They went from an in incredibly well managed drug company and then management decided to develop their own drugs and make mistakes. It is difficult to unwind these problems. Turning around a company like this will be difficult because of the debt. This is a highly speculative stock.
biotechnologypharmaceutical
DON'T BUY
A generic drug company that has had troubled times as pricing is becoming very competitive. Buyers are consolidating and squeezing margins. They have a MS drug that was a market leader, but now there are others competing. He would rather own brand name drug companies that can become leaders in their field.
biotechnologypharmaceutical
DON'T BUY
It has done very well. But they made a huge acquisitions three years ago, taking on a lot of debt. They went through several CEOs. The generic drug space is tough and competitive. Generic drug pricing is limited as we head towards a U.S. election; generics are a target of politicians. Also, there are many lawsuits in the generic drug industry. Generics should do better after the election.
biotechnologypharmaceutical
Has just got back into the stock after being away for several years. It is the largest generic company globally. He likes buying pharmaceutical stocks when they are out of favour. This has a drug called COPAXON for multiple sclerosis, which is just coming off patent. Acquired Allergan’s generic business, and the integration has had a few rocky times. Looking forward, the valuation is as cheap as it has been in a very long time. Dividend yield of 3.79%. (Analysts’ price target is $52.48.)